Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

NRF2 pathway

7

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

6

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2013

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Multiple sclerosis

7

Arthritis

6

Ischemic stroke

6

Relapsing forms of multiple sclerosis

6

Unknown

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

7

Primary

7

Palliative

6

Secondary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Biogen|Fumapharm

6

Yaish, P. et al.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

PUBCHEM

7

EPA CompTox

6

ECHA (EC/EINECS)

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

IMMUNOSUPPRESSANTS

1

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

IMMUNOSUPPRESSANTS

1

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other immunosuppressants

1

Other nervous system drugs

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Monomethyl Fumarate

45IUB1PX8R

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutathione S-transferase

Hydroxycarboxylic acid receptor 2

Nuclear factor erythroid 2-related factor 2

Conditions:

Relapsing forms of multiple sclerosis

Multiple sclerosis

Ischemic stroke

Relapsing forms of multiple sclerosis

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...

riasis (trade name Fumaderm). Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

AG-126

7YA4AMD1JC

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase BTK

Epidermal growth factor receptor

Conditions:

Spinal cord trauma

Diabetes mellitus

Multiple sclerosis

AG-126 is the putative protein tyrosine kinase (PTK) inhibitor. It was found to rescue mice from lethal consequences of bacterial lipopolysaccharide (LPS) administration in a model of septic shock. AG126 treatment has beneficial effects in experiment...

al autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. AG126 alleviates the clinical symptoms, diminishes encephalitogenic Th17 differentiation, reduces inflammatory CNS infiltration as well as microglia activation and attenuates myelin damage. AG-126 have recently been shown to protect from acute kidney injury in experimental animal models of ischemia-reperfusion and sepsis-induced injury. AG-126 modulates secondary damage in experimental spinal cord trauma.

DIMETHYL FUMARATE

FO2303MNI2

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutathione S-transferase

Hydroxycarboxylic acid receptor 2

Nuclear factor erythroid 2-related factor 2

Conditions:

Relapsing forms of multiple sclerosis

Multiple sclerosis

Ischemic stroke

Relapsing forms of multiple sclerosis

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...

riasis (trade name Fumaderm). Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

DIROXIMEL FUMARATE

K0N0Z40J3W

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutathione S-transferase

Hydroxycarboxylic acid receptor 2

Nuclear factor erythroid 2-related factor 2

Conditions:

Relapsing forms of multiple sclerosis

Multiple sclerosis

Ischemic stroke

Relapsing forms of multiple sclerosis

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...

riasis (trade name Fumaderm). Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

DIMETHYL MALEATE

K39366X5N0

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutathione S-transferase

Hydroxycarboxylic acid receptor 2

Nuclear factor erythroid 2-related factor 2

Conditions:

Relapsing forms of multiple sclerosis

Multiple sclerosis

Ischemic stroke

Relapsing forms of multiple sclerosis

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...

riasis (trade name Fumaderm). Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

TEPILAMIDE FUMARATE

KOS9TZ09CM

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutathione S-transferase

Hydroxycarboxylic acid receptor 2

Nuclear factor erythroid 2-related factor 2

Conditions:

Relapsing forms of multiple sclerosis

Multiple sclerosis

Ischemic stroke

Relapsing forms of multiple sclerosis

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...

riasis (trade name Fumaderm). Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

MONOMETHYL MALEATE

U3UT1G2B9N

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Glutathione S-transferase

Hydroxycarboxylic acid receptor 2

Nuclear factor erythroid 2-related factor 2

Conditions:

Relapsing forms of multiple sclerosis

Multiple sclerosis

Ischemic stroke

Relapsing forms of multiple sclerosis

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...

riasis (trade name Fumaderm). Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1